Phase 2 N=100 Intravaginal LACTIN-V for Prevention of Recurrent Urinary Tract Infection
Urinary Tract Infection
Primary: Incidence of Urinary Tract Infection — 7; 13 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=83 Efficacy and Safety of Ranibizumab (Intravitreal Injections) Versus Laser Treatment in Patients With Visual Impairment Due to Diabetic Macular Edema
Diabetic Macular Edema · Visual Impairment
Primary: Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) — 9.41; 5.79 letters
Phase 2 N=24 Varenicline and Smoking Cessation in Schizophrenia
Schizophrenia · Smoking Cessation
Primary: Smoking Abstinence - Serum/Urine Measurements — 198.67; 207; 213.8; 22.57 ng/mL — p=>0.05
Phase 2 N=42 Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy
Hepatocellular Carcinoma
Primary: Progression Free Survival (PFS) in Participants With Unresectable Hepatocellular Cancer Treated With the Monoclonal Antibody Ramucirumab — 4.0 months
Phase 2 N=120 A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder
Major Depressive Disorder
Primary: Hamilton Depression Rating Scale (HAM-D-17) Scores — 20.1; 19.9; 14.7; 15.6 points
Phase 2 N=139 Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs
Major Depressive Disorder
Primary: The Primary Outcome Measure Will be Response Rates (50% Decrease in HAM-D-17 Scores) During Phase 2 — 35.2; 20.5 Percentage of patients
Phase 2 N=30 Papillary Serous Carcinoma of the Endometrium
Endometrial Cancer
Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants
Phase 2 N=54 Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)
Depression
Primary: Part 1: Number of Participants With Moderate Intensity Adverse Events (AEs) — 2; 0; 1; 2 participants
Phase 2 N=39 Bracing and Strengthening for Posterior Tibial Tendon Dysfunction
Posterior Tibial Tendon Dysfunction
Primary: Foot Function Index(FFI) — 16.0; 12.7; 8.1; 8.3 units on a scale
Phase 2 N=21 Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
Cervical Cancer · Endometrial Cancer · Ovarian Cancer
Primary: Toxicity Rates of Patients Treated With Concurrent Avastin and Daily Pelvic Radiation With no Other Concurrent Chemotherapy — 766 Events
Phase 2 N=122 Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus
Barrett Esophagus · Esophageal Cancer
Primary: Change in Mean Tissue Prostaglandin E2 (PGE2) Concentration as Determined From Barrett's Research Mucosal Biopsy Samples — -67.6; -123.9; -174.9 pg/mL — p=0.0955
Phase 2 N=170 Biobehavioral Interventions for HIV-negative, Stimulant Using Men Who Have Sex With Men
HIV Seroconversion · Stimulant Abuse
Primary: Time From Exposure to Truvada Initiation — 32.8; 33.0 hours
Phase 2 N=13 Effect of Galantamine on Smoking Abstinence
Nicotine Addiction
Primary: Number of Days of Abstinence During a 7-day Quit Attempt — 5 days
Phase 2 N=46 Neural Substrates in Nicotine Withdrawal
Tobacco Use Disorder
Primary: Measure of Brain Activity: Blood Oxygen Level Dependent (BOLD) fMRI Signal Change During the "N-back" Working Memory Task (Brain Region: Right Dorsolateral Prefrontal…
Phase 2 N=6 Immune Tolerance Study With Aldurazyme® (Laronidase)
Mucopolysaccharidosis I
Primary: Number of Participants Who Achieved Immune Tolerance Induction — 0; 1 participants